Acorda Therapeutics, Inc. reported unaudited sales results for the fourth quarter and full year of 2015. For the quarter, the company reported net sales of $121 million.

For the full-year, net sales were $436 million, an increase of approximately 19% from 2014.

The company provided 2016 guidance for AMPYRA net revenue of $475 million - $485 million, research and development (R&D) expense of $165 million -$175 million, and sales, general and administrative (SG&A) expense of $195 million -$205 million.